Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Strategic Alliance Partners

May 09, 2025

Joseph C. Murray, MD, highlights positive treatment shifts that have shaped the BRAF V600E–mutant non–small cell lung cancer treatment paradigm.

April 30, 2025

Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.

April 23, 2025

Dr Christenson discusses the capabilities of the Oncodetect test, its clinical applications and pronostic value, and findings from the Alpha-CORRECT study.

March 30, 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, HER2+ breast cancer, non¬–muscle-invasive bladder cancer, and ovarian cancer.

March 24, 2025

Syed Abbas Ali, MBBS, discusses treatment decisions for patients with R/R myeloma for whom CAR T-cell therapy and bispecific antibodies are both options.

March 04, 2025

Evangelia Vlachou, MD, discusses response rates with enfortumab vedotin alone or with pembrolizumab in patients with upper tract urothelial cancer.

February 02, 2025

Benjamin P. Levy, MD, discusses the current clinical and developmental statuses of several ADCs for patients with non–small cell lung cancer.

February 02, 2025

Russell Hales, MD, discusses clinical data that challenge the use of post-operative radiotherapy in patients with non–small cell lung cancer.

January 15, 2025

Syed Abbas Ali, MBBS, discusses the identification of novel targets for patients with multiple myeloma who previously progressed on BCMA-targeted agents.

January 14, 2025

Benjamin P. Levy, MD, shares insight on current challenges with TROP2-directed antibody-drug conjugates in NSCLC.

December 10, 2024

Stephanie Gaillard, MD, PhD, details cervical and ovarian cancer NCCN guideline updates, as well as unmet needs associated with molecular markers.

November 22, 2024

Syed Abbas Ali, MBBS, discusses how CAR T-cell therapies and bispecific antibodies have altered treatment in relapsed/refractory multiple myeloma.

November 06, 2024

Julie R. Brahmer, MD, MSc, FASCO, details practice-changing indications and notable data in the early-stage, neo(adjuvant), and metastatic NSCLC settings.

September 08, 2024

Event-free survival improved with perioperative nivolumab vs neoadjuvant nivolumab plus chemotherapy in resectable NSCLC, according to a comparison of 2 trials.

June 13, 2024

Camidge and Cooper discuss Cooper’s career as a hospital chaplain, the focus of her writing, and the importance of meeting patients where they are.

May 30, 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in May 2024.

May 30, 2024

Dr Levy discusses the indication for trastuzumab deruxtecan in HER2+ NSCLC, other ADCs in development, and where the future of ADCs in NSCLC is headed.

April 18, 2024

Eric S. Christenson, MD, discusses the potential benefit of copanlisib plus nivolumab in PIK3CA-mutant microsatellite stable colorectal cancer.

April 15, 2024

Benjamin Levy, MD, discusses the utility of multidisciplinary treatment in lung cancer care.

April 11, 2024

Experts from across the oncology field highlight their biggest takeaways and the hottest topics from the 2024 AACR Annual Meeting.